Myriad Loses Again: Patents On Genetic Testing Ruled Invalid
from the now-go-forth-and-innovate dept
Back in 2013, the Supreme Court struck down patents that Myriad Genetics had obtained on naturally-occuring DNA sequences linked to breast cancer. As a result of that judgment, other companies started offering diagnostic tests based on the genes in question. Myriad claimed that despite losing patents on the DNA, its patents on tests based on that DNA were still valid, and took legal action to stop others from offering similar services. As we reported earlier this year, a federal district court judge refused to grant Myriad a preliminary injunction against one of those new entrants, and now the genetic testing patents have been ruled invalid, as Bloomberg reports:Myriad Genetics Inc. (MYGN) can't block competitors' DNA tests to determine risk for breast and ovarian cancer after a U.S. appeals court said three patents on the tests never should have been issued.That's great news for women who can now choose freely from among a range of diagnostic options, often at prices substantially less than comparable testing offered by Myriad. It means that Myriad's monopoly on data derived from those tests has been broken: thanks to its patents, it has created the world's largest database of mutations in breast cancer genes. Most importantly, perhaps, it opens up the field of gene-based diagnostic testing to allow new entrants to experiment and innovate more freely. That, rather than granting monopolies to a few companies, is far more likely to lead to new medical breakthroughs, products and services.
The patents cover products of nature and ideas that aren't eligible for legal protection, the U.S. Court of Appeals for the Federal Circuit said in an opinion posted today on the court's docket. The court upheld a trial judge's decision to allow the competing tests, including those made by Ambry Genetics Corp., to remain on the market.
Follow me @glynmoody on Twitter or identi.ca, and +glynmoody on Google+
Thank you for reading this Techdirt post. With so many things competing for everyone’s attention these days, we really appreciate you giving us your time. We work hard every day to put quality content out there for our community.
Techdirt is one of the few remaining truly independent media outlets. We do not have a giant corporation behind us, and we rely heavily on our community to support us, in an age when advertisers are increasingly uninterested in sponsoring small, independent sites — especially a site like ours that is unwilling to pull punches in its reporting and analysis.
While other websites have resorted to paywalls, registration requirements, and increasingly annoying/intrusive advertising, we have always kept Techdirt open and available to anyone. But in order to continue doing so, we need your support. We offer a variety of ways for our readers to support us, from direct donations to special subscriptions and cool merchandise — and every little bit helps. Thank you.
–The Techdirt Team
Filed Under: brca1, brca2, dna, dna patents, gene patents, genetic testing, patents
Companies: myriad genetics
Reader Comments
Subscribe: RSS
View by: Time | Thread
Quit thinking small-time!
[ link to this | view in chronology ]
[ link to this | view in chronology ]
Re:
Yeah, Hollywood refused to classify anything smuttier than X...
[ link to this | view in chronology ]
'No friend of mine'
Really, how would you react if, upon asking 'So how was your day/week?' someone responded with 'Been filing legal papers attempting to stop other companies from offering cheaper breast cancer screening'. To me at least, that would probably be a 'Shunned for life' event there, someone so focused on money and profits that they were willing to try and squash others offering vital medical tests, would not be someone I would care to associate with.
[ link to this | view in chronology ]
Re: 'No friend of mine'
[ link to this | view in chronology ]
[ link to this | view in chronology ]
Re: they might sweep the next thing under the rug until they are sure they can patent it
[ link to this | view in chronology ]
[ link to this | view in chronology ]
Must be shitloads of useful info in there. Or will they just shift their business model to charging for access? Or do they already do that?
[ link to this | view in chronology ]